DUBLIN – Advicenne SA set out its stall this week with plans to raise up to €35 million (US$41 million) in an IPO on the Euronext in Paris, in order to continue clinical development of its lead therapy, ADV-7103, and to initiate the commercial rollout of the product in Europe.